[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Kawamoto T, Akisue T, Marui T, Nakatani T, Hitora T, Fujita I, Kurosaka M, Yamamoto T: Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines. Anticancer Res; 2004 Sep-Oct;24(5A):2675-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
  • BACKGROUND: Malignant fibrous histiocytoma (MFH) is one of the most common high-grade sarcomas in bone and soft tissue and, due to its chemo-resistance, the prognosis of the disease is poor.
  • STI571 might be a potent chemotherapeutic agent for human MFHs.
  • [MeSH-major] Histiocytoma, Benign Fibrous / drug therapy. Piperazines / pharmacology. Protease Inhibitors / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Benzamides. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Imatinib Mesylate. Proto-Oncogene Proteins c-kit / biosynthesis. Proto-Oncogene Proteins c-kit / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor beta / biosynthesis. Receptor, Platelet-Derived Growth Factor beta / genetics

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15517872.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protease Inhibitors; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


2. Tsuda N, Murayama K, Ishida H, Matsunaga K, Komiya S, Itoh K, Yamada A: Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res; 2001 May;19(3):346-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SART3 was detected at protein levels in 100% of the osteosarcoma cell lines (n = 20), in 50% of the musculoskeletal tumor tissue specimens (n = 32), and at notable levels in 67% of osteosarcoma tissues (n = 9) and malignant fibrous histiocytosis tissues (n = 9), respectively.
  • SART3-derived peptides at positions 109-118 and 315-323 induced HLA-A24-restricted tumor-specific cytoxic T lymphocytes from peripheral blood mononuclear cells of patients with osteosarcoma or malignant fibrous histiocytosis.
  • These results suggest that the SART3 protein and its derived peptides could be molecules appropriate for use in specific immunotherapies for approximately 60% of HLA-A24+ patients with osteosarcoma or malignant fibrous histiocytosis.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Bone Neoplasms / metabolism. Histiocytoma, Benign Fibrous / metabolism. Osteosarcoma / metabolism. Peptide Fragments / pharmacology. RNA-Binding Proteins / biosynthesis. T-Lymphocytes, Cytotoxic / drug effects
  • [MeSH-minor] Cell Survival / drug effects. Cytotoxicity Tests, Immunologic. Histocompatibility Antigens Class I / immunology. Humans. Immunotherapy. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11398844.001).
  • [ISSN] 0736-0266
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Histocompatibility Antigens Class I; 0 / Peptide Fragments; 0 / RNA-Binding Proteins; 0 / SART3 protein, human
  •  go-up   go-down


3. Yoshitani K, Honoki K, Morishita T, Kido A, Miyauchi Y, Mii Y, Takakura Y: Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571. In Vivo; 2003 May-Jun;17(3):255-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
  • We have recently established rat osteosarcoma and malignant fibrous histiocytoma (MFH) cell lines.
  • These data suggested that STI571 tyrosine kinase inhibitor plays a role in blocking or slowing the rate of growth of MFH and osteosarcoma cells expressing tyrosine kinase type receptor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Histiocytoma, Benign Fibrous / drug therapy. Osteosarcoma / drug therapy. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
  • [MeSH-minor] Animals. Benzamides. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Imatinib Mesylate. Proto-Oncogene Proteins c-kit / genetics. RNA, Messenger / genetics. Rats

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12929576.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


Advertisement
4. Koswig S, Budach V: [The role of radiotherapy in the treatment of bone neoplasms]. Chirurg; 2002 Dec;73(12):1174-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of radiotherapy in the treatment of bone neoplasms].
  • Primary malignant bone neoplasms are relatively rare.
  • The most common bone tumors are osteosarcoma,Ewing's sarcoma,chondrosarcoma, fibrosarcoma,malignant fibrous histiocytoma of bone, giant cell tumor, aneurysmal bone cyst and chordoma.
  • The most common bone neoplasms and the role of the radiotherapy are discussed in these chapter.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Chondrosarcoma / radiotherapy. Osteosarcoma / radiotherapy. Sarcoma, Ewing / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Cysts, Aneurysmal / radiotherapy. Bone Cysts, Aneurysmal / surgery. Child. Child, Preschool. Chordoma / radiotherapy. Chordoma / surgery. Clinical Trials as Topic. Combined Modality Therapy. Dose Fractionation. Female. Fibrosarcoma / radiotherapy. Fibrosarcoma / surgery. Follow-Up Studies. Giant Cell Tumors / radiotherapy. Giant Cell Tumors / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Palliative Care. Postoperative Care. Radiotherapy Dosage. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12491046.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


5. Lucas DR, Miller PR, Mott MP, Kronick JL, Unni KK: Arthroplasty-associated malignant fibrous histiocytoma: two case reports. Histopathology; 2001 Dec;39(6):620-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arthroplasty-associated malignant fibrous histiocytoma: two case reports.
  • We report the clinicopathological findings in two cases of arthroplasty-associated malignant fibrous histiocytoma (MFH) and review the literature.
  • Both were destructive femoral bone tumours that appeared 2 and 8 years post-total hip arthroplasty, and pursued aggressive clinical courses.
  • The histology was similar in both tumours, consisting of high-grade, pleomorphic sarcoma with numerous osteoclastic giant cells, prominent phagocytic activity, and entrapped particles of bone cement.
  • A number of materials and factors related to arthroplasty procedure, such as metal corrosion, wear debris, osteonecrosis, and chronic inflammation, have been implicated as causative agents.
  • [MeSH-major] Arthroplasty, Replacement. Bone Neoplasms / pathology. Histiocytoma, Benign Fibrous / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11903581.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 43
  •  go-up   go-down


6. Burak Z, Ersoy O, Moretti JL, Erinç R, Ozcan Z, Dirlik A, Sabah D, Basdemir G: The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med; 2001 Sep;28(9):1341-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of multidrug resistance (MDR), which is in part due to the overexpression of P-glycoprotein (Pgp), is a major problem in neoadjuvant therapy of malignant musculoskeletal tumours.
  • In conclusion, the initial uptake of 99mTc-MIBI in bone and soft tissue sarcomas did not correlate with Pgp expression.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Muscle Neoplasms / radionuclide imaging. P-Glycoprotein / analysis. Radiopharmaceuticals. Sarcoma / radionuclide imaging. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Child. Drug Resistance, Multiple. Female. Histiocytoma, Benign Fibrous / chemistry. Histiocytoma, Benign Fibrous / radionuclide imaging. Histiocytoma, Benign Fibrous / therapy. Humans. Immunohistochemistry. Male. Middle Aged. Neoadjuvant Therapy. Osteosarcoma / chemistry. Osteosarcoma / radionuclide imaging. Osteosarcoma / therapy. Phenotype

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11585293.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / P-Glycoprotein; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


7. Honoki K, Yoshitani K, Tsujiuchi T, Mori T, Tsutsumi M, Morishita T, Takakura Y, Mii Y: Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines. Oncol Rep; 2004 May;11(5):1025-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.
  • In this study, we focused on the effects of flavopiridol on chemically-induced rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma (MFH) cell lines showing different pattern of p16INK4a status.
  • These data indicate that flavopiridol shows cell type specific inhibition and possibly acts in a more compensatory manner for endogenous p16INK4a function in tumor cells having the aberrations of p16INK4a gene.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis / drug effects. Bone Neoplasms / pathology. Flavonoids / pharmacology. Histiocytoma, Benign Fibrous / pathology. Lung Neoplasms / pathology. Osteosarcoma / pathology. Piperidines / pharmacology
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Line, Tumor. Cyclin D1 / genetics. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cyclin-Dependent Kinases / genetics. DNA Methylation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Promoter Regions, Genetic / genetics. Proto-Oncogene Proteins / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15069542.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Flavonoids; 0 / Piperidines; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 136601-57-5 / Cyclin D1; 45AD6X575G / alvocidib; EC 2.7.11.22 / Cdk4 protein, rat; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


8. Patel SJ, Lynch JW Jr, Johnson T, Carroll RR, Schumacher C, Spanier S, Scarborough M: Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol; 2002 Oct;25(5):489-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who demonstrated a "poor response" (PR) received four cycles of high-dose methotrexate alternating with two cycles of ifosfamide/etoposide and two cycles of cisplatin/etoposide after the surgery.
  • Twelve of 19 evaluable patients (63%) were treated according to the GR arm and 7 according to the PR arm.
  • Patients treated on the GR arm had DFS and OS of 75% and 83%, respectively, whereas patients on the PR arm had DFS and OS of 57%.
  • Intensive neoadjuvant chemotherapy is effective and moderately well tolerated in patients with de novo osteosarcoma.
  • The outcome data suggest that lack of a near complete response to preoperative chemotherapy reflects inherent biologic resistance to chemotherapy and hence a poor prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Ifosfamide / administration & dosage. Middle Aged. Neoadjuvant Therapy. Prospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12393991.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement